Clinical trial
A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)
NCT04066504 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional, Multi-national, Multi-center Post-authorization Safety Study (PASS) to Assess the Long Term Safety and Tolerability of Odomzo (Sonidegib) Administered in Patients With Locally Advanced Cell Carcinoma (laBCC)
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 11, 2019
- Completion date
- March 14, 2025
- Enrollment
- 323 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.